SiRui Bio

SiRui Bio (Beijing SiRuiKangRui Bio-technology) is a pioneering biopharmaceutical company headquartered in Beijing, China, specializing in the development of next-generation circular RNA (circRNA) therapeutics. Founded in 2021, the company leverages its proprietary circular RNA platform and lipid nanoparticle (LNP) delivery systems to create more stable and durable protein-encoding medicines compared to traditional linear mRNA. Its research focus spans oncology, where it develops circRNA-encoded cytokines, as well as infectious disease vaccines and protein replacement therapies for rare genetic disorders. SiRui Bio has attracted significant investment from top-tier venture capital firms including Decheng Capital and GL Ventures to advance its innovative RNA pipeline toward clinical trials. The company is led by industry veterans with extensive experience in cell and gene therapy from organizations such as Legend Biotech and Janssen.